Showing results (321-330 of 447) with videos related to
Sort By:
Pageof 45
Circulation|February 24, 2017
Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation: A Randomized, Open-Label Clinical Trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control])Ratika Parkash, George A Wells, John L Sapp, et al.Heart Rhythm|July 11, 2025
Atrial fibrillation progression in patients with device-detected subclinical atrial fibrillation: Insights from the ARTESiA trialGiuseppe Boriani, William F McIntyre, Chinthanie Ramasundarahettige, et al.Journal of Cardiovascular Electrophysiology|September 30, 2011
Sentinel symptoms in patients with unexplained cardiac arrest: from the cardiac arrest survivors with preserved ejection fraction registry (CASPER)Andrew D Krahn, Jeffrey S Healey, Christopher S Simpson, et al.Circulation|November 2, 2011
Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probandsRaymond W Sy, Christian van der Werf, Ishvinder S Chattha, et al.Stroke|January 4, 2024
Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct OutcomesEric E Smith, Ashkan Shoamanesh, Lizhen Xu, et al.Circulation|September 4, 2024
Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA TrialWilliam F McIntyre, Alexander P Benz, Jeff S Healey, et al.Journal of the American Heart Association|September 13, 2021
LVS-HARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a World-Wide RegistryLinda S B Johnson, Jonas Oldgren, Tyler W Barrett, et al.Journal of the American College of Cardiology|February 7, 2024
Bleeding Outcomes in Patients Treated With Asundexian in Phase II TrialsJohn W Eikelboom, Hardi Mundl, John H Alexander, et al.European Heart Journal. Cardiovascular Pharmacotherapy|June 30, 2021
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trialThomas Vanassche, Peter Verhamme, Sonia S Anand, et al.Circulation|March 18, 2014
Temporal relationship between subclinical atrial fibrillation and embolic eventsMichela Brambatti, Stuart J Connolly, Michael R Gold, et al.Pageof 45